# A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects

> **NCT02637193** · PHASE1 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 54 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Venlafaxine
- **DRUG:** Moxifloxacin
- **DRUG:** Drug - placebo

## Key facts

- **NCT ID:** NCT02637193
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2021-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02637193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02637193, "A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02637193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*